Manual curation of mapped sequences using IGV (30,31) revealed that the TP53 gene was mutated in all but one of the Mayo Clinic low stage HGS ovarian carcinomas (Table 3) and at high mutant frequency when results in these carcinomas were combined with the 28 low stage HGS carcinomas of TCGA (Supplementary Table S8). This evidence concerns the gene TP53 and ovarian carcinoma.